论文信息 - Multilocus Inherited Neoplasia Allele Syndrome (MINAS): an update - 字舞流文

Multilocus Inherited Neoplasia Allele Syndrome (MINAS): an update

A. Need | T. Hearn | M. Bleda | L. Moutsianas | D. Kasperavičiūtė | E. Williams | S. Leigh | A. Tucci | A. Sosinsky | A. L. Taylor Tavares | A. Kousathanas | N. Murugaesu | M. Tischkowitz | C. Boustred | P. Arumugam | R. Bevers | A. Stuckey | J. Whitworth | M. Tanguy | F. Minneci | J. Ambrose | G. Chan | T. Fowler | T. Hubbard | R. Jackson | L. J. Jones | L. Lahnstein | F. J. Lopez | F. Maleady-Crowe | M. Mueller | C. Odhams | D. Perez-Gil | J. Pullinger | T. Rahim | T. Rogers | K. Savage | K. Sawant | A. Siddiq | A. Sieghart | S. Thompson | M. Welland | K. Witkowska | S. Wood | E. Maher | Avgi Andreou | F. Minneci | A. Rendon | F. Boardman-Pretty | M. Caulfield | A. Giess | A. Hamblin | S. Henderson | C. Patch | M. Pereira | R. Scott | E. Thomas | J. C. P. R. M. F. C. R. H. M. J. G. C. T. A. A. S. T. Ambrose Arumugam Bevers Bleda Boardman-Pretty | I. Leong | H. Brittain | M. McEntagart | P. O‘Donovan | M. Kayikci | S. Smith | Anthony McGuigan | A. McGuigan

[1] Jaana M. Hartikainen,et al. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. , 2021, The New England journal of medicine.

[2] L. Forétova,et al. Identification of Germline Mutations in Melanoma Patients with Early Onset, Double Primary Tumors, or Family Cancer History by NGS Analysis of 217 Genes , 2020, Biomedicines.

[3] V. Vysotskaia,et al. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations , 2019, Cancer.

[4] F. Nielsen,et al. High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer , 2019, npj Genomic Medicine.

[5] Ville Mustonen,et al. The repertoire of mutational signatures in human cancer , 2018, Nature.

[6] C. Lázaro,et al. Does multilocus inherited neoplasia alleles syndrome have severe clinical expression? , 2018, Journal of Medical Genetics.

[7] C. Turnbull,et al. Consensus for genes to be included on cancer panel tests offered by UK genetics services: guidelines of the UK Cancer Genetics Group , 2018, Journal of Medical Genetics.

[8] Russell Bonneville,et al. Landscape of Microsatellite Instability Across 39 Cancer Types. , 2017, JCO precision oncology.

[9] M. Cobleigh,et al. Hereditary diffuse gastric cancer and lynch syndromes in a BRCA1/2 negative breast cancer patient , 2017, Breast Cancer Research and Treatment.

[10] B. Talseth-Palmer. The genetic basis of colonic adenomatous polyposis syndromes , 2017, Hereditary cancer in clinical practice.

[11] Yi Cao,et al. Familial risk for lung cancer. , 2017, Oncology letters.

[12] Hajime Uno,et al. Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13] T. Pal,et al. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer , 2016 .

[14] Olufunmilayo I. Olopade,et al. Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women , 2016, Breast Cancer Research.

[15] Peter A. Jones,et al. Epigenetic Determinants of Cancer. , 2016, Cold Spring Harbor perspectives in biology.

[16] S. Hodgson,et al. Diagnosis and Management of Hereditary Thyroid Cancer. , 2016, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[17] J. Norton,et al. Multiple Endocrine Neoplasia: Genetics and Clinical Management. , 2015, Surgical oncology clinics of North America.

[18] T. Dörk,et al. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations , 2014, Breast Cancer Research and Treatment.

[19] E. Braggio,et al. Genetic Factors and Pathogenesis of Waldenström’s Macroglobulinemia , 2013, Current Oncology Reports.

[20] R. Govindarajan,et al. Applications of immunohistochemistry , 2012, Journal of pharmacy & bioallied sciences.

[21] K. Nathanson,et al. Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background. , 2012, Cancer genetics.

[22] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.

[23] H T Lynch,et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications , 2009, Clinical genetics.

[24] S. Hodgson,et al. Mechanisms of inherited cancer susceptibility , 2007, Journal of Zhejiang University SCIENCE B.

[25] C B Begg,et al. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[26] K. Kinzler,et al. Mechanisms underlying losses of heterozygosity in human colorectal cancers , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27] S Wacholder,et al. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. , 1999, American journal of human genetics.

[28] P. Hartge,et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[29] F. Collins,et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals , 1995, Nature Genetics.